New York, NY -- (SBWIRE) -- 01/17/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI), IsoRay, Inc (NYSEMKT:ISR), Athersys, Inc (NASDAQ:ATHX), AirMedia Group Inc (ADR) (NASDAQ:AMCN)
Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI) showed a volume of 1.80 million shares by the end of last trade whereas the average volume of the stock remained 1.23 million shares. The stock opened the session at $9.29 but then moved to $9.82. At that price, the stock showed a positive performance of 6.05%. Spectrum Pharmaceuticals, Inc. (Spectrum) is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. In the United States, the Company markets three oncology drugs, FUSILEV, FOLOTYN and ZEVALIN and also markets ZEVALIN outside of the United States,
Will SPPI Continue To Move Higher? Find Out Here
IsoRay, Inc (NYSEMKT:ISR) opened the session at $0.80 and closed the session at $0.834. The stock showed a positive performance of 2.63% in previous trading session. Traded with volume of 1.81 million shares in the prior session and the average volume of the stock remained 1.22 million shares. IsoRay, Inc. (IsoRay) develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. IsoRay International LLC (International) is a wholly owned subsidiary of the Company.
For How Long ISR will fight for Profitability? Read This Trend Analysis report
Athersys, Inc (NASDAQ:ATHX) opened the session at $4.00 and closed the session at $4.03. The stock showed a positive performance of 1.77% in previous trading session. The beta of the stock remained 0.63. Athersys Inc. is a biopharmaceutical company engaged in the field of regenerative medicine. During the year ended December 31, 2011 the Company is developing its platform product, MultiStem, a allogeneic stem cell product that has been evaluated in two completed Phase I clinical trials and as of December 31, 2011, is being evaluated in two ongoing Phase II clinical trials.
Why Should Investors Buy ATHX After The Recent Gain? Just Go Here and Find Out
AirMedia Group Inc (ADR) (NASDAQ:AMCN) the stock decreased -5.83% and finished the session at $2.26. Traded with volume of 1.75 million shares in the prior session and the average volume of the stock remained 695,200.00 shares. The beta of the stock remained 1.63. AirMedia Group Inc is a holding company. The Company is an operator of out-of-home advertising platforms in China. As of March 1, 2012, the Company operated approximately 3,368 digital frames in 34 airports, 1,367 of which were standalone digital frames,
Will AMCN Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)